Abstract
The clinical effects of newly synthesized penicillin, PC-904 were examined, and effectiveness rate was 60% against relapse in chronic bronchitis and 80% against acute pneumonia. Background analysis of the above mentioned cases revealed that majority cases of the former were not effective to the conventional antibiotics, and many of the latter were accompanied with chronic respiratory diseases.
Severe side effects were not observed, though 4 cases (8. 8%) of abnormal liver function tests and 1 case of thrombocytopenia were indicated.
From these data, PC-904 seems to be useful for various kinds of infections such as relapse of chronic infections or acute ones in respiratory tracts. This drug is considered to he worthwhile for serious respiratory infectious diseases, because it shows antibacterial effect on therapy-resistant gram-negativtbacilli, such as Pseudomonas aeruginosa.
